Research and experimental development on natural sciences and engineering
AGIANA PHARMACEUTICALS AS
Revenue 2024
NOK 535,000
Operating profit
NOK −4.7m
Equity
NOK 13.4m
Incorporated
2021
Share capital
NOK 37,000
Key figures · 2024
Current ratio
19.53
Equity ratio
94.9%
Key figures over time · 2024
| Key figures | 2024 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Operating margin (%%) | -871.7% | |
| Net margin (%%) | -842.0% | |
| Return on assets (%%) | -33.0% | |
| Likviditet | ||
| Current ratio | 19.53 | |
| Working capital | 13.4m | |
| Soliditet | ||
| Equity ratio (%%) | 94.9% | |
| Debt-to-equity ratio | 0.05 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.